Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/6831
Title
Cefditoren and ceftriaxone enhance complement-mediated immunity in the presence of specific antibodies against antibiotic-resistant pneumococcal strains
Author(s)
Ramos-Sevillano, Elisa ISCIII | Rodriguez-Sosa, Cinthya ISCIII | Cafini, Fabio | Giménez, Maria-Jose | Navarro, Ana ISCIII | Sevillano, David | Alou, Luis | García, Ernesto | Aguilar, Lorenzo | Yuste, Jose Enrique ISCIII
Date issued
2012-09-05
Citation
PLoS One. 2012;7(9):e44135
Language
Inglés
Document type
journal article
Abstract
BACKGROUND: Specific antibodies mediate humoral and cellular protection against invading pathogens such as Streptococcus pneumoniae by activating complement mediated immunity, promoting phagocytosis and stimulating bacterial clearance. The emergence of pneumococcal strains with high levels of antibiotic resistance is of great concern worldwide and a serious threat for public health. METHODOLOGY/PRINCIPAL FINDINGS: Flow cytometry was used to determine whether complement-mediated immunity against three antibiotic-resistant S. pneumoniae clinical isolates is enhanced in the presence of sub-inhibitory concentrations of cefditoren and ceftriaxone. The binding of acute phase proteins such as C-reactive protein and serum amyloid P component, and of complement component C1q, to pneumococci was enhanced in the presence of serum plus either of these antibiotics. Both antibiotics therefore trigger the activation of the classical complement pathway against S. pneumoniae. C3b deposition was also increased in the presence of specific anti-pneumococcal antibodies and sub-inhibitory concentrations of cefditoren and ceftriaxone confirming that the presence of these antibiotics enhances complement-mediated immunity to S. pneumoniae. CONCLUSIONS/SIGNIFICANCE: Using cefditoren and ceftriaxone to promote the binding of acute phase proteins and C1q to pneumococci, and to increase C3b deposition, when anti-pneumococcal antibodies are present, might help reduce the impact of antibiotic resistance in S. pneumoniae infections.
MESH
Acute-Phase Proteins | Animals | Anti-Bacterial Agents | Antibodies | Ceftriaxone | Cephalosporins | Complement Activation | Complement C1q | Complement C3c | Drug Resistance, Microbial | Egtazic Acid | Flow Cytometry | Humans | Immune System | Mice | Phagocytosis | Streptococcus pneumoniae | beta-Lactams
Online version
DOI
Collections